Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

4D Molecular Therapeutics, Inc. - Common Stock (NQ:FDMT)

11.77 +0.68 (+6.13%)
Streaming Delayed Price Updated: 12:44 PM EDT, Jul 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 4D Molecular Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Why Semtech Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket ↗
Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares rose 50.5% to $0.20 in pre-market trading after dropping 5% on Wednesday. 
Via Benzinga
News headline image
4D Molecular Therapeutics Stock Is Trading Higher Today - Here's Why ↗
4D Molecular Therapeutics (NASDAQ: FDMT) announced interim data from the 4D-710 Phase 1/2 AEROW trial for  
Via Benzinga
News headline image
4DMT Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at the ECFS 46th Annual Meeting
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Latest Analyst Ratings for 4D Molecular Therapeutics ↗
 
Via Benzinga
News headline image
SVB Securities Maintains Market Perform Rating for 4D Molecular Therapeutics: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Expert Ratings for 4D Molecular Therapeutics ↗
 
Via Benzinga
News headline image
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Present Interim Data from 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis Lung Disease at the European Cystic Fibrosis Society (ECFS) 46th Annual Meeting
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
$50M Bet On Coinbase Global? Check Out These 4 Stocks Insiders Are Buying ↗
Although US stocks closed mixed on Thursday, there were a few notable insider trades. 
Via Benzinga
News headline image
4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4D Molecular Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Underwriters’ full exercise of option brings gross proceeds to $138.0 million 
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
What's Going On With 4D Molecular Therapeutics Stock Today ↗
4D Molecular Therapeutics (NASDAQ: FDMT) shares are trading lower after the company released interim clinical data from the Phase 1 Dose Exploration stage of the 4D-150 Phase 1/2 PRISM trial for wet... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Why NETGEAR Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) jumped 147.9% to $0.2479. Evelo Biosciences shares dropped 33% on Wednesday after the company announced top-line data from the fourth cohort of its... 
Via Benzinga
News headline image
Dow Surges 100 Points; Meta Platforms Reports Upbeat Results ↗
U.S. stocks traded higher this morning, with the Dow Jones gaining around 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.38% to 33,429.66 while the NASDAQ rose 0.88%... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
4DMT Presents Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ARVO 2023
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Acquires Complement Pathway Inhibitor Payload for 4D-175 Product Candidate for Geographic Atrophy
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Present Interim Data from 4D-150 Phase 1/2 PRISM Clinical Trial for Wet AMD at ARVO 2023, and Promotes Robert Kim, M.D. to Chief Medical Officer
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
7 Biotech Stocks Sitting in the Sweet Spot ↗
Biotech stocks have the potential for massive profits if their companies are successful in developing drugs that are safe and marketable. 
Via InvestorPlace
News headline image
4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4D Molecular Discloses Updated Data From Currently Paused Fabry Disease Cardiomyopathy Study ↗
 
Via Benzinga
News headline image
4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium™
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Present Interim Clinical Data from INGLAXA Phase 1/2 Trials of 4D-310 for Fabry Disease Cardiomyopathy at 19th Annual WORLDSymposium™
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4D Molecular Therapeutics to Participate in the SVB Securities Global Biopharma Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.